Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Curasen Therapeutics Announces $54.5M Series A Financing With Industry Veterans At Helm To Develop Drugs Targeting Novel Mechanism For The Treatment Of Neurodegenerative Diseases
Venture Capital

Curasen Therapeutics Announces $54.5M Series A Financing With Industry Veterans At Helm To Develop Drugs Targeting Novel Mechanism For The Treatment Of Neurodegenerative Diseases

by vcaonline.com posted 11months ago 272 views
CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases Kathleen Sereda Glaub Appointed Executive Chair and Anthony Ford, PhD, Named Chief Executive Officer New Leaf Venture Partners Leads Top-Tier Investor Syndicate SAN MATEO, Calif., October 17, 2018-- CuraSen Therapeutics, Inc., a privately held biotechnology company focused on developing therapies to treat neurodegenerative diseases, today announced the closing of a $54.5 million Series A financing.

In this article